ERBB2 and breast carcinoma: The authors reported the design and synthesis of a trastuzumab-PROTAC conjugate (Ab-PROTAC 3), which degraded its BRD4 target selectively in HER2-positive breast cancer cell lines, while sparing HER2-negative cells.